Meningococcal vaccine refers to any of the vaccines used to prevent infection by Neisseria meningitidis.Different versions are effective against some or all of the following types of meningococcus: A, C, W-135,and Y.The vaccines are between 85 and 100% effective for at least two years.They result in a decrease in meningitis and sepsis among populations where they are widely used.They are given either by injection into a muscle or just under the skin.

Market Analysis and Insights: Global Meningococcal Infections Vaccine Market
The global Meningococcal Infections Vaccine market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Meningococcal Infections Vaccine market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Meningococcal Infections Vaccine market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Meningococcal Infections Vaccine market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Meningococcal Infections Vaccine market.

Global Meningococcal Infections Vaccine Scope and Market Size
Meningococcal Infections Vaccine market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Meningococcal Infections Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Quadrivalent (Serogroups A, C, W-135, and Y)
Bivalent (Serogroups C and Y)
Serogroup A
Serogroup B
Serogroup X

Segment by Application
Hospital
Clinic

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Creative Biolabs(USA)
SERUM INSTITUTE OF INDIA PVT.LTD.(India)